| Adaptive is comercial-stage company. Co is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Co.'s clinical diagnostic product, clonoSEQ, is the test authorized by the Food and Drug Administration for the detection and monitoring of minimal residual disease in patients with multiple myeloma and B cell acute lymphoblastic leukemia and is being validated for patients with other blood cancers. Co.'s commercial research product, immunoSEQ, primarily serves as its underlying research and development engine to develop and validate its clinical pipeline. The ADPT YTD return is shown above.
The YTD Return on the ADPT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ADPT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADPT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.